Non-respiratory symptoms including poor sleep, fatigue, pain, anxiety, and depressive symptoms were prevalent among adults with cystic fibrosis (AwCF) and persisted after 1 year of follow-up, based on ...

Evolution in the management of cystic fibrosis has led to more patients surviving to adulthood, but data on the trends and comorbidities in adult patients, and the impact of disparities in access to ...

This study update could positively impact Vertex Pharmaceuticals and Moderna’s stock performance, as successful results may enhance their competitive position in the cystic fibrosis treatment market.

Please provide your email address to receive an email when new articles are posted on . The study reported elevated adjusted rates for four non-pulmonary complications in those with vs. without cystic ...

Funds allocated to the Adult Cystic Fibrosis Assistance Program in recent years haven't been distributed because there is no longer a program or process to disburse the aid. Getty Images. As many New ...

A local man has been recognized for his lifelong efforts to help those impacted by cystic fibrosis, a rare respiratory disease. John O’Neil was honored on his 70th birthday when Kettering Mayor Peggy ...

Arcturus Therapeutics (($ARCT)) announced an update on their ongoing clinical study. Study Overview: Arcturus Therapeutics is conducting a Phase 2 ...

BONITA SPRINGS, Fla.--(BUSINESS WIRE)--Erida Kazmaj, 14, has never known a year where she had not been hospitalized at least four times. Born with cystic fibrosis, she’s battled chronic symptoms ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...